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Identity 
HGNC (Hugo): GPC5 
Location: 13q31.3 
Local order: Centromere - MIR17HG - GPC5 - GPC6 
- DCT - TGDS - GPR180 - SOX21 - telomere. 
DNA/RNA 
Note 
The gene spans 1.47 Mb of DNA, comprising 8 exons. 
Transcription 




572 amino acids; 64 kDa protein (core protein). GPC5 
is a heparan sulfate proteoglycan (HSPG), that is bound 
to the cell surface by a glycosyl-phosphatidylinositol 
(GPI) anchor. 
Expression 
GPC5 is expressed mainly in fetal tissues, including 
brain, lung and liver. In the adult, expression is 
primarily in brain tissue. 
Localisation 
Attached to the cell membrane by a GPI anchor. 
 
Schematic of glypican protein structure at the cell surface. The protein is held in the plasma membrane by a GPI anchor at the 
carboxyl terminus. Numerous glycosoaminoglycan (GAG) attachment sites close to the membrane surface allow heparin and chondroitin 
sulphate chains to be attached to the core protein (shown in green). The amino terminal end of the protein is a globular structure held 
together by a conserved set of cysteine residues forming disulphide bridges. (Picture reproduced from Filmus and Selleck, 2001). 
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Function 
The precise functions of GPC5 have yet to be fully 
established. HSPGs are common constituents of cell 
surfaces and the extracellular matrix (ECM), with 
essential functions in cell growth and development 
(Burgess and Macaig, 1989; Andres et al., 1992). 
Glypicans appear to be expressed predominantly during 
development, with expression levels changing in a 
stage- and tissue-specific manner, suggesting their 
involvement in morphogenesis (Sing and Filmus, 
2002). As they can bind numerous ligands and be 
associated with a variety of receptors, they act as co-
receptors for a number of heparin-binding growth 
factors, modulating their activity. The heparan sulfate 
modifications of glypicans can mediate interactions 
with growth factors or ECM proteins, but ligands and 
ECM proteins can also bind through motifs in the core 
proteins (Mythreye and Blobe, 2009). Glypicans can be 
secreted from the cell surface, such soluble forms can 
also bind growth factors. Evidence to date suggests that 
glypicans can regulate Wnt, hedgehog, fibroblast 
growth factor and bone morphogenetic protein 
pathways. The effect on these pathways may be 
stimulatory or inhibitory depending on cellular context 
(Gallet et al., 2008; Capurro et al., 2008; Kreuger et al., 
2004; Yan and Lin, 2007; Grisaru et al., 2001; Yan et 
al., 2010). 
GPC5 expression has been shown in the developing 
central nervous system, limbs and kidneys of mice, and 
its expression in mammalian fetal tissues suggests roles 
in growth and differentiation during development 
(Veugelers et al., 1997; Saunders et al., 1997; Luxardi 
et al., 2007). Its almost exclusive expression in adult 
brain tissue suggests a possible role in controlling 
neurotropic factors and maintaining neural function. 
Homology 
GPC5 is a member of the glypican family of HSPGs, of 
which six members (GPC1, GPC2, GPC3, GPC4, 
GPC5, GPC6) have been identified in mammals. GPC3 
is the most homologous member to GPC5 in humans. 
There is approximately 20-60% sequence homology 
between family members, including conservation of a 
pattern of 14 cysteine residues. Homolog glypican-like 





Amplification of 13q31-32 has been shown in poor 
prognosis liposarcomas, breast cancers and neurologic 
tumours (Reardon et al., 2000; Ojopi et al., 2001; 
Ullmann et al., 2001; Schmidt et al., 2005). 
Amplification of 13q31-32 has also been shown in 
approximately 20% of alveolar rhabdomyosarcoma, as  
well as gain of GPC5 copies in both alveolar and 
embryonal rhabdomyosarcoma (Gordon et al., 2000). 
GPC5 is overexpressed in the majority of 
rhabdomyosarcomas compared with normal skeletal 
muscle and has been shown to modulate responses to 
FGF2 in rhabdomyosarcoma cells (Williamson et al., 
2007). GPC5 may also potentiate hedgehog signalling 
in these cells as it can bind to both Hedgehog and the 
Patched receptor (Li et al., 2010a). A recent genome 
wide association study has linked polymorphisms in 
GPC5 to risk of lung cancer in never-smokers (Li et al., 
2010b). The high-risk allele was coincident with lower 
expression of GPC5, suggesting that the role of GPC5 
is likely to be tumour type-specific in an analogous 
manner to GPC3, the closest family member to GPC5. 
Developmental disorders 
Note 
Studies on the role of GPC5 in disease are still 
relatively limited. In humans, deletions of the 13q31-32 
region are associated with the 13q deletion syndrome, a 
developmental disorder with a wide phenotypic 
spectrum including mental and growth retardation, 
congenital defects and craniofacial dysmorphy, and 
GPC5 is suggested as a candidate gene for digital 
malformations in this syndrome (Quelin et al., 2009). 
Correspondingly, GPC5 is also a candidate gene for 
postaxial polydactyly type A2, which is associated with 
duplication of 13q31-32 (van der Zwaag et al., 2010). 
Multiple sclerosis 
Note 
Several genome wide association studies have 
identified GPC5 as having a potential role in Multiple 
Sclerosis (MS) (Baranzini et al., 2009; Lorentzen et al., 
2010). Several different GPC5 polymorphisms were 
also highlighted in an independent study designed to 
determine which genes are associated with efficacy of 
interferon beta therapy in MS (Byun et al., 2008), this 
finding has subsequently been confirmed in a separate 
study (Cenit et al., 2009). HSPGs are found in dense 
networks in active MS plaques, where they may 
sequester pro-inflammatory cytokines. 
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